PS1-14: Utilization and Effectiveness of KRAS Test... [Clin Med Res. 2010] - PubMed result

Clin Med Res. 2010 Dec;8(3-4):192.
PS1-14: Utilization and Effectiveness of KRAS Testing for Colorectal Cancer.

Feigelson H, Goddard K, Rahm AK, Pawloski P, McCarty C, Onitilo A, Lawrence K, Davis R, Potosky A.

Abstract

Background: New genomic and personalized medicine (GPM) applications have the potential to enhance our ability to screen for disease predisposition and treatment responsiveness. Surveying colorectal cancer (CRC) tissue for mutations in the KRAS gene is one such test that can help decide how to treat patients with metastatic colorectal cancer (mCRC). KRAS testing provides an opportunity for oncologists to tailor the use of anti-EGFR therapy to increase treatment effectiveness and potentially minimize adverse events. The FDA has recently changed the labeling of anti-EGFR therapies to indicate that it is not effective for the treatment of patients with KRAS mutations. KRAS testing has already become standard clinical practice in many settings. In this study, we will assess the patterns of diffusion and utilization of KRAS testing and evaluate the characteristics of patients, providers, and health systems as they relate to the uptake of KRAS testing. We will also conduct a comparative analysis of KRAS testing for mCRC patients treated in community practices to evaluate its effectiveness in terms of both progression-free survival and overall survival. Methods: This study will include a total of 800 mCRC cases diagnosed between January 1, 2005 and July 31, 2010 from 7 HMORN sites. Using electronic records at each site, we will capture information on relevant patient characteristics including disease characteristics, comorbidities, history of all cancer-directed therapies, acute complications, receipt of palliative care and contextual socioeconomic variables. We will use chart review to supplement, or in some cases verify, the electronic data. Conclusion: The study will serve as a model for evaluating the potential impact of GPM applications to improve health outcomes, reduce costs, and influence patient and physician decision-making in the area of personalized therapies.

PMID: 21177579 [PubMed - in process]PMCID: PMC3006508
Free PMC Article
PS1-14: Utilization and Effectiveness of KRAS Test... [Clin Med Res. 2010] - PubMed result


PS1-14: Utilization and Effectiveness of KRAS Testing for Colorectal Cancer
PS1-14: Utilization and Effectiveness of KRAS Testing for Colorectal Cancer

PS1-14: Utilization and Effectiveness of KRAS Testing for Colorectal Cancer -- Feigelson et al. 8 (34): 192 -- Clinical Medicine & Research